vs

Side-by-side financial comparison of DT Midstream, Inc. (DTM) and Esperion Therapeutics, Inc. (ESPR). Click either name above to swap in a different company.

DT Midstream, Inc. is the larger business by last-quarter revenue ($317.0M vs $168.4M, roughly 1.9× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 27.3%). Over the past eight quarters, DT Midstream, Inc.'s revenue compounded faster (14.9% CAGR vs 10.6%).

Oneok, Inc. ONE-oak, stylized as ONEOK, is an American oil and gas midstream operator headquartered in Tulsa, Oklahoma. It provides the oil and gas industry with gathering, processing, fractionation, transportation, and storage services. The company is part of the Fortune 500 and S&P 500. Oneok was founded as Oklahoma Natural Gas Company in 1906, but it changed its corporate name to Oneok in 1980.

Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.

DTM vs ESPR — Head-to-Head

Bigger by revenue
DTM
DTM
1.9× larger
DTM
$317.0M
$168.4M
ESPR
Growing faster (revenue YoY)
ESPR
ESPR
+116.4% gap
ESPR
143.7%
27.3%
DTM
Faster 2-yr revenue CAGR
DTM
DTM
Annualised
DTM
14.9%
10.6%
ESPR

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
DTM
DTM
ESPR
ESPR
Revenue
$317.0M
$168.4M
Net Profit
$111.0M
Gross Margin
Operating Margin
49.2%
50.6%
Net Margin
35.0%
Revenue YoY
27.3%
143.7%
Net Profit YoY
52.1%
EPS (diluted)
$1.07
$0.32

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DTM
DTM
ESPR
ESPR
Q4 25
$317.0M
$168.4M
Q3 25
$314.0M
$87.3M
Q2 25
$309.0M
$82.4M
Q1 25
$303.0M
$65.0M
Q4 24
$249.0M
$69.1M
Q3 24
$248.0M
$51.6M
Q2 24
$244.0M
$73.8M
Q1 24
$240.0M
$137.7M
Net Profit
DTM
DTM
ESPR
ESPR
Q4 25
$111.0M
Q3 25
$115.0M
$-31.3M
Q2 25
$107.0M
$-12.7M
Q1 25
$108.0M
$-40.5M
Q4 24
$73.0M
Q3 24
$88.0M
$-29.5M
Q2 24
$96.0M
$-61.9M
Q1 24
$97.0M
$61.0M
Operating Margin
DTM
DTM
ESPR
ESPR
Q4 25
49.2%
50.6%
Q3 25
49.4%
-11.4%
Q2 25
50.2%
8.6%
Q1 25
48.8%
-34.0%
Q4 24
45.4%
-6.4%
Q3 24
49.2%
-31.0%
Q2 24
53.3%
3.5%
Q1 24
51.7%
52.5%
Net Margin
DTM
DTM
ESPR
ESPR
Q4 25
35.0%
Q3 25
36.6%
-35.9%
Q2 25
34.6%
-15.4%
Q1 25
35.6%
-62.2%
Q4 24
29.3%
Q3 24
35.5%
-57.2%
Q2 24
39.3%
-83.9%
Q1 24
40.4%
44.3%
EPS (diluted)
DTM
DTM
ESPR
ESPR
Q4 25
$1.07
$0.32
Q3 25
$1.13
$-0.16
Q2 25
$1.04
$-0.06
Q1 25
$1.06
$-0.21
Q4 24
$0.73
$-0.14
Q3 24
$0.90
$-0.15
Q2 24
$0.98
$-0.33
Q1 24
$0.99
$0.34

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DTM
DTM
ESPR
ESPR
Cash + ST InvestmentsLiquidity on hand
$54.0M
$167.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$4.7B
$-302.0M
Total Assets
$10.1B
$465.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DTM
DTM
ESPR
ESPR
Q4 25
$54.0M
$167.9M
Q3 25
$98.0M
$92.4M
Q2 25
$74.0M
$86.1M
Q1 25
$83.0M
$114.6M
Q4 24
$68.0M
$144.8M
Q3 24
$77.0M
$144.7M
Q2 24
$73.0M
$189.3M
Q1 24
$41.0M
$226.6M
Total Debt
DTM
DTM
ESPR
ESPR
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$3.4B
Q3 24
Q2 24
Q1 24
Stockholders' Equity
DTM
DTM
ESPR
ESPR
Q4 25
$4.7B
$-302.0M
Q3 25
$4.7B
$-451.4M
Q2 25
$4.7B
$-433.5M
Q1 25
$4.6B
$-426.2M
Q4 24
$4.6B
$-388.7M
Q3 24
$4.2B
$-370.2M
Q2 24
$4.2B
$-344.2M
Q1 24
$4.2B
$-294.3M
Total Assets
DTM
DTM
ESPR
ESPR
Q4 25
$10.1B
$465.9M
Q3 25
$10.1B
$364.0M
Q2 25
$10.0B
$347.1M
Q1 25
$9.9B
$324.0M
Q4 24
$9.9B
$343.8M
Q3 24
$8.6B
$314.1M
Q2 24
$9.0B
$352.3M
Q1 24
$9.0B
$373.1M
Debt / Equity
DTM
DTM
ESPR
ESPR
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.72×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DTM
DTM
ESPR
ESPR
Operating Cash FlowLast quarter
$161.0M
$45.2M
Free Cash FlowOCF − Capex
$30.0M
FCF MarginFCF / Revenue
9.5%
Capex IntensityCapex / Revenue
41.3%
0.0%
Cash ConversionOCF / Net Profit
1.45×
TTM Free Cash FlowTrailing 4 quarters
$441.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DTM
DTM
ESPR
ESPR
Q4 25
$161.0M
$45.2M
Q3 25
$274.0M
$-4.3M
Q2 25
$185.0M
$-31.4M
Q1 25
$247.0M
$-22.6M
Q4 24
$152.0M
$-35.0M
Q3 24
$205.0M
$-35.3M
Q2 24
$165.0M
$-7.2M
Q1 24
$241.0M
$53.8M
Free Cash Flow
DTM
DTM
ESPR
ESPR
Q4 25
$30.0M
Q3 25
$131.0M
Q2 25
$104.0M
Q1 25
$176.0M
Q4 24
$62.0M
Q3 24
$124.0M
$-35.5M
Q2 24
$84.0M
$-7.3M
Q1 24
$143.0M
$53.8M
FCF Margin
DTM
DTM
ESPR
ESPR
Q4 25
9.5%
Q3 25
41.7%
Q2 25
33.7%
Q1 25
58.1%
Q4 24
24.9%
Q3 24
50.0%
-68.7%
Q2 24
34.4%
-9.9%
Q1 24
59.6%
39.0%
Capex Intensity
DTM
DTM
ESPR
ESPR
Q4 25
41.3%
0.0%
Q3 25
45.5%
0.0%
Q2 25
26.2%
0.0%
Q1 25
23.4%
0.0%
Q4 24
36.1%
0.0%
Q3 24
32.7%
0.3%
Q2 24
33.2%
0.1%
Q1 24
40.8%
0.1%
Cash Conversion
DTM
DTM
ESPR
ESPR
Q4 25
1.45×
Q3 25
2.38×
Q2 25
1.73×
Q1 25
2.29×
Q4 24
2.08×
Q3 24
2.33×
Q2 24
1.72×
Q1 24
2.48×
0.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DTM
DTM

Pipeline Segment$173.0M55%
Gathering Segment$144.0M45%

ESPR
ESPR

Collaboration Revenue$124.7M74%
Products$43.7M26%

Related Comparisons